



Spermosens provides an update on the Generation 3 clinical study

Spermosens AB (publ) (“Spermosens” or the “Company”) provides an update on the ongoing clinical study of JUNO-Checked Generation 3 at the Reproductive Medicine Centre (RMC) in Malmö. Recruitment is progressing ahead of plan, with 43 patients included to date. The Company’s ambition remains, as previously communicated, to complete the study during 2026.

The Generation 3 clinical study is a central element in the Company’s strategy to demonstrate the clinical value of JUNO-Checked and to pursue commercialization through partnerships. The study evaluates JUNO-Checked, which measures the sperm cell’s ability to bind to the egg, in couples undergoing IVF treatment. The clinical data forms the basis for these partner discussions, which the Company continues to advance in parallel with the study.

Recruitment has progressed faster than expected so far, supported by a strong collaboration with the clinic and a high willingness among patients to participate. This is an encouraging marker of progress. Recruitment will pause during the clinic’s summer break and resume mid August.

In parallel with the study, the Company is adjusting the parameters of how the test is performed to produce the most accurate results. Validating a new diagnostic technology is a demanding process, and as with any clinical study the outcome and timing are not certain.

Spermosens will participate in the Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London on 5–8 July 2026. The Company has been selected to present the results of its first clinical study, completed in 2025 with the second-generation JUNO-Checked sensor, and will meet companies active in the field.

Tore Duvold, CEO of Spermosens, comments, “Recruitment ahead of plan is an important step, as it provides us the data we need to conclude the study, and it reflects a strong collaboration with the clinic and the patients participating. Presenting our first clinical study at ESHRE next week is a great opportunity to engage with the field, and completing the Generation 3 study during 2026 remains our priority.”

For more information, please contact:

Tore Duvold, CEO

E-mail: info@spermosens.com

About Spermosens AB

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company’s shares are

listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.